Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -618.74% is 81% below its 5-year average of -342.01%, around the middle of its 5-year range (-880.70%–-101.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.61% above its 12-month average of -742.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -618.74%.
RETURN ON EQUITY (ROE)
-618.74%
RETURN ON EQUITY (ROE) AVG TTM
-742.02%
RETURN ON EQUITY (ROE) AVG 3Y
-455.92%
RETURN ON EQUITY (ROE) AVG 5Y
-342.01%
RETURN ON EQUITY (ROE) AVG 10Y
-216.22%
RETURN ON EQUITY (ROE) AVG 15Y
-216.22%
RETURN ON EQUITY (ROE) AVG 20Y
-223.73%
CURRENT VS TTM AVG
+16.61%
CURRENT VS 3Y AVG
-35.71%
CURRENT VS 5Y AVG
-80.91%
CURRENT VS 10Y AVG
-186.17%
CURRENT VS 15Y AVG
-186.17%
CURRENT VS 20Y AVG
-176.56%
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-1517.63%
vs the sector median at left
GT Biopharma, Inc.
Market Cap
$7.77M
Return on Equity (ROE)
-618.74%
TTM Avg
-742.02%
3Y Avg
-455.92%
5Y Avg
-342.01%
Market Cap
$7.75M
Return on Equity (ROE)
-91.75%
TTM Avg
-295.51%
3Y Avg
-88.38%
5Y Avg
-106.70%
Market Cap
$7.64M
Return on Equity (ROE)
-225.67%
TTM Avg
-236.53%
3Y Avg
-220.64%
5Y Avg
-186.37%
Market Cap
$7.31M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$8.42M
Return on Equity (ROE)
-31.99%
TTM Avg
-84.19%
3Y Avg
-171.49%
5Y Avg
-138.23%
Market Cap
$7.03M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$7.01M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$6.88M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$8.83M
Return on Equity (ROE)
-7.36%
TTM Avg
-85.10%
3Y Avg
-73.72%
5Y Avg
-96.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | $7.77M | -618.74% | -742.02% | -455.92% | -342.01% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -91.75% | -295.51% | -88.38% | -106.70% |
| Longeveron Inc. (LGVN)vs › | $7.64M | -225.67% | -236.53% | -220.64% | -186.37% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.42M | -31.99% | -84.19% | -171.49% | -138.23% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -218.65% | -54.74% | -35.36% | -35.36% |
| KALA BIO, Inc. (KALA)vs › | $7.01M | -111.46% | -348.97% | -374.13% | -408.25% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -370.16% | -148.31% | -87.53% | -43.20% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.83M | -7.36% | -85.10% | -73.72% | -96.61% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -108.00% | -445.77% | -254.63% | -239.85% |
ROE
-618.7%
ROA
-381.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -618.74% |
| 2026-03-31 | -629.74% |
| 2025-12-31 | -789.30% |
| 2025-09-30 | -880.70% |
| 2025-06-30 | -791.59% |
| 2024-09-30 | -588.89% |
| 2024-06-30 | -206.14% |
| 2024-03-31 | -181.40% |
| 2023-12-31 | -101.62% |
| 2023-09-30 | -102.14% |
| 2023-06-30 | -124.83% |
| 2023-03-31 | -120.06% |
| 2022-12-31 | -177.98% |
| 2022-09-30 | -208.86% |
| 2022-06-30 | -206.57% |
| 2022-03-31 | -189.87% |
| 2021-12-31 | -264.78% |
| 2021-09-30 | -171.40% |
| 2021-06-30 | -143.57% |
| 2021-03-31 | -268.37% |
| 2018-06-30 | -63.28% |
| 2018-03-31 | -59.25% |
| 2017-12-31 | -57.39% |
| 2017-09-30 | -55.67% |
| 2007-12-31 | 61.73% |
| 2007-09-30 | -639.59% |
| 2006-09-30 | -274.13% |
| 2006-06-30 | -200.68% |
| 2006-03-31 | -151.77% |
| 2005-12-31 | -105.96% |
| 2005-09-30 | -32.62% |
| 2005-06-30 | -25.90% |
| 2005-03-31 | -40.24% |
| 2004-12-31 | -44.90% |
| 2004-03-31 | -143.27% |
| 2003-12-31 | -90.92% |
| 2003-09-30 | -81.51% |
| 2003-06-30 | -109.07% |
